Veterinary World

     Open access and peer reviewed journal  

ISSN (Online): 2231-0916


Home l Editorial board l Instructions for authors l Reviewer guideline l Open access policy l Archives l FAQ

Open Access

Research (Published online: 26-08-2016)

18. Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis - Daniela Proverbio, Eva Spada, Giada Bagnagatti de Giorgi and Roberta Perego

Veterinary World, 9(8): 904-908



   doi: 10.14202/vetworld.2016.904-908



Daniela Proverbio: Department of Veterinary Medicine, University of Milan, Via Celoria 10, 20133 Milan, Italy;

Eva Spada: Department of Veterinary Medicine, University of Milan, Via Celoria 10, 20133 Milan, Italy;

Giada Bagnagatti de Giorgi: Department of Veterinary Medicine, University of Milan, Via Celoria 10, 20133 Milan, Italy;

Roberta Perego: Department of Veterinary Medicine, University of Milan, Via Celoria 10, 20133 Milan, Italy;


Received: 21-02-2016, Accepted: 19-07-2016, Published online: 26-08-2016


Corresponding author: Daniela Proverbio, e-mail:

Citation: Proverbio D, Spada E, de Giorgi GB, Perego R (2016) Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis, Veterinary World, 9(8): 904-908.

Aim: The aim of this study was to evaluate changes in proteinuria in dogs naturally infected with visceral leishmaniasis, following treatment with miltefosine (MLF) and allopurinol.

Materials and Methods: Medical records of 40 dogs with leishmaniasis, treated with 2 mg/kg MLF every 24 h PO and 10 mg/kg allopurinol every 12 h for 28 days were reviewed. 20 dogs were included in the study, and clinical staging was performed following guidelines of the Canine leishmaniasis (CanL) Working Group, and dogs were categorized for proteinuria according to the International Renal Interest Society (IRIS) staging system. Clinical score, indirect fluorescent antibody test titer, serum total protein, gamma globulin (IgG), serum creatinine and urea concentration, and urine protein creatinine ratio (UP/C) were recorded at the time of diagnosis before the start of therapy (D0) and at the end of 28 days of therapy (D28).

Results: Following the CanL Working Group staging, all 20 dogs were classified as the clinical Stage C (Clinical disease) before and after the cycle of treatment. Before the cycle of therapy, dogs were categorized according to the IRIS staging system, as: 9/20 non-proteinuric (NP), 7/20 borderline proteinuric (BP), and 4/20 proteinuric (P). After treatment, 12/20 dogs were NP, 7/20 were BP, and 1/20 was P. There was a significant change in UP/C values before and after one cycle of treatment with MLF. In detail, after 28 days of therapy, 2 of 9 NP dogs became BP, 3 of the 7 BP dogs became NP, and 2 of the 4 P dogs became NP.

Conclusion: This study showed a significant decrease in UP/C values occurred after one cycle of treatment with MLF and allopurinol in dogs naturally affected with CanL. This suggests that MLF does not increase proteinuria, and the use of MLF could be considered for the management of dogs with leishmaniasis, particularly in those with impaired renal function at the time of diagnosis.

Keywords: canine leishmaniasis therapy, proteinuric kidney disease, renal function, urine protein creatinine.

1. Amusategui, I., Sainz, A., Rodríguez, F. and Tesouro, M.A. (2003) Distribution and relationships between clinical and biopathological parameters in canine leishmaniosis. Eur. J. Epidemiol., 18: 147-56.
2. Solano-Gallego, L., Koutinas, A., Mirò, G., Cardoso, L., Pennisi, M.G., Ferrer, L., Bourdeau, P., Oliva, G. and Baneth, G. (2009) Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmanosis. Vet. Parasitol., 65: 1-18.
3. Nieto, R.T., Giunchetti, R.C., Carneiro, C.M., Vitor, R.W., Coura-Vital, W., Quaresma, P.F., Ker, H.G., de Melo, L.A., Gontijo, C.M. and Reis, A.B. (2010) Relationship of leishmania – Specific IgG levels and IgG avidity with parasite density and clinical sings in canine leishmaniosis. Vet. Parasitol., 169: 248-257.
4. Solano-Gallego, L., Riera, C., Roura, X., Iniesta, L., Gallego, M., Valladares, J.E., Fisa, R., Castillejo, S., Alberola, J., Ferrer, L., Arboix, M. and Portús, M. (2001) Leishmania infantum-specific IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet. Parasitol., 96: 265-276.
5. Sardomikelakis, M.N. (2009) Advances in the pathogenesis of canine leishmaniosis: Epidemiologic implications Vet. Dermatol., 20: 471-489.
6. Koutinas, A.F. and Koutinas, C.K. (2014) Pathologic mechanisms underlying the clinical findings in canine leishmaniosis due to Leishmania infantum/chagasi. Vet. Pathol., 51: 525-539.
7. Palacio, J., Liste, F. and Gascon, M. (1995) Urinary protein/creatinine ratio in the evaluation of renal failure in canine leishmaniosis. Vet. Rec., 137: 567-568.
8. Bianciardi, P., Brovida, C., Valente, M., Aresu, L., Cavicchioli, L., Vischer, C., Giroud, L. and Castagnaro, M. (2009) Administration of miltefosine and meglumine antimoniate in healthy dogs: Clinicophatological evaluation of the impact on the Kidney. Toxicol. Pathol., 37: 770-775.
9. Oliva, G., Roura, X., Crotti, A., Maroli, M., Castagnaro, M., Grandoni, L., Lubas, G., Paltrinieri, S., Zatelli, A. and Zini, E. (2010) Guidelines for treatment of leishmaniasis in dogs. J. Am. Vet. Med. Assoc., 236: 1192-1198.
10. Noli, C. and Auxilia, S.T. (2006) Treatment of canine old world visceral leishmaniasis: A systematic review. Vet. Dermatol., 16: 213-232.
11. Manna, L., Vitale, F., Reale, S., Picillo, E., Neglia, G., Vescio, F. and Gravino, A.E. (2009) Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet. J., 182: 441-445.
12. Andrade, H.M., Toledo, V.P., Pinheiro, M.B., Guimarães, T.M., Oliveira, N.C., Castro, J.A., Silva, R.N., Amorim, A.C., Brandão, R.M., Yoko, M., Silva, A.S., Dumont, K., Ribeiro, M.L. Jr., Bartchewsky, W. and Monte, S.J. (2011) Evalutation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil. Vet. Parasitol., 2011: 83-90.
13. Maia, C., Nunes, M., Marques, M., Henriques, S., Rolão, N. and Campino, L. (2013) In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Exp. Parasitol., 135: 36-41.
14. Solano-Gallego, L., Mirò, G., Koutinas, A., Cardoso, L., Pennisi, M.G., Ferrer, L., Bourdeau, P., Oliva, G. and Baneth, G. (2011) LeishVet guidelines for the practical management of canine leishmaniosis. Parasit. Vector, 4: 86.
PMid:21599936 PMCid:PMC3125381
15. Proverbio, D., Spada, E., De Giorgi, G.B. and Perego, R. (2014) Failure of miltefosine treatment in two dogs naturally affected with Leishmania infantum. Vet. Med., Article ID: 2014: 640151, 6.
16. Roura, X., Fondati, A., Lubas, G., Gradoni, L., Maroli, M., Oliva, G., Paltrinieri, S., Zatelli, A. and Zini, E. (2013) Prognosis and monitoring of leishmaniosis in dogs: A working group report. Vet. J., 198: 43-47.
17. Aresu, L., Benali, S., Ferro, S., Vittone, V., Gallo, E., Brovida, C. and Castagnaro, M. (2012) Light and electron microscopic analysis of consecutive renal biopsy specimens from Leishmania-seropositive dogs. Vet. Pathol., 5: 753-760.
18. Zatelli, A., Borgarelli, M., Santilli, R., Bonfanti, U., Nigrisoli, E., Zanatta, R., Tarducci, A. and Guarraci, A. (2003) Glomerular lesions in dogs infected with Leishmania organisms. Am. J. Vet. Res. 64: 558-561.
19. García-Martínez, J.D., Martinez-Subiela, S., Tvarijonaviciute, A., Caldin, M. and Ceron, J.J. (2015) Urinary ferritin and cystatin C concentrations at different stages of kidney disease in leishmaniotic dogs. Res. Vet. Sci., 99: 204-207.
20. Ibba, F., Mangiagalli, G. and Paltrinieri, S. (2016) Urinary gamma-glutamyl transferase (GGT) as a marker of tubular proteinuria in dogs with canine leishmaniasis, using sodium dodecylsulphate (SDS) electrophoresis as a reference method. Vet. J., 210: 89-91.
21. Poli, A., Abramo, F., Mancianti, F., Nigro, M., Pieri, S. and Bionda, A. (1991) Renal involvent in canine leiahmaniasis. Nephron, 57: 444-452.
22. Braga, E.T., Leite, J.H., Rosa, F.A., Tivelli, P., Araújo, A.M., Almeida, B.F., Ferrari, H.F., Ciarlini, P.C., Machado, G.F. and Marcondes, M. (2015) Hypertension and its correlation with renal lesions in dogs with leishmaniosis. Rev. Bras. Parasitol. Vet., 24: 45-51.
23. Miró, G., Oliva, G., Cruz, I., Ca-avate, C., Mortarino, M., Vischer, C. and Bianciardi, P. (2009) Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet. Dermatol., 20: 397-404.
24. Woerly, W., Maynard, L., Sanquer, A. and Eun, H.M. (2009) Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitol. Res., 105: 463-469.
25. Mateo, M., Maynard, L., Vischer, C., Bianciardi, P. and Miró, G. (2009) Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitol. Res., 105: 155-162.
26. Manna, L., Corso, R., Galiero, G., Cerrone, A., Muzj, P. and Gravino, A.E. (2015) Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versusmiltefosine plus allopurinol. Parasit. Vector, 8: 289.
PMid:26017164 PMCid:PMC4458061